Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States

被引：0
作者：
Penn, Courtney Alexis [1 ]
Wong, Melissa Spring [2 ]
Walsh, Christine [2 ]
机构：
[1] Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2020.07.050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 50 条
[21]   Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States [J].
Aguiar-Ibanez, Raquel ;
Hardern, Chloe ;
van Hees, Frank ;
Lee, Dawn ;
Patel, Anubhav ;
Chhabra, Nitika ;
Baluni, Gargi ;
Amonkar, Mayur ;
Lai, Yizhen ;
Xu, Ruifeng ;
Massaad, Rachid ;
Fogelman, David .
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :469-480
[22]   Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland [J].
Critchlow, Simone ;
Bullement, Ash ;
Crabb, Simon ;
Jones, Robert ;
Christoforou, Katerina ;
Amin, Amerah ;
Xiao, Ying ;
Kapetanakis, Venediktos ;
Benedict, Agnes ;
Chang, Jane ;
Kearney, Mairead ;
Eccleston, Anthony .
FUTURE ONCOLOGY, 2024, 20 (08) :459-470
[23]   A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands [J].
Smalbrugge, David ;
Walsteijn, Tim ;
de Feijter, Jeantine ;
Suelmann, Britt ;
Kearney, Mairead ;
Benedict, Agnes ;
Kapetanakis, Venediktos ;
van Beekhuizen, Sophie .
ONCOLOGY AND THERAPY, 2025,
[24]   Biomarker testing to guide first-line PARP inhibitor maintenance for patients with advanced ovarian cancer after response to first-line platinum chemotherapy: A cost-effectiveness study [J].
Fan, Lin ;
Elsea, David ;
Muston, Dominic ;
Mihai, Adela ;
Monberg, Matthew .
GYNECOLOGIC ONCOLOGY, 2022, 166 :S195-S195
[25]   Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status [J].
Penn, Courtney A. ;
V. Carballo, Erica ;
Walsh, Christine S. ;
Zivanovic, Oliver ;
Kim, Kenneth H. .
GYNECOLOGIC ONCOLOGY REPORTS, 2022, 41
[26]   Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status [J].
Penn, Courtney ;
Walsh, Christine ;
Kim, Kenneth .
GYNECOLOGIC ONCOLOGY, 2021, 162 :S11-S11
[27]   Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States [J].
Borse, Rebekah H. ;
Ramakrishnan, Karthik ;
Gandhi, Jyotika ;
Dhankhar, Praveen ;
Chirovsky, Diana .
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :954-965
[28]   Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States [J].
Guy, Holly ;
Walder, Lydia ;
Fisher, Mark .
PHARMACOECONOMICS, 2019, 37 (03) :391-405
[29]   COST-EFFECTIVENESS OF NIRAPARIB VERSUS ROUTINE SURVEILLANCE AND OLAPARIB FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH OVARIAN CANCER IN THE UNITED STATES [J].
Fisher, M. ;
Guy, H. ;
Walder, L. .
VALUE IN HEALTH, 2018, 21 :S32-S32
[30]   Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States [J].
Holly Guy ;
Lydia Walder ;
Mark Fisher .
PharmacoEconomics, 2019, 37 :391-405
12345